Halozyme Therapeutics, Inc..
HALO.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel oncology therapies. The company's primary focus is on its ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that facilitates the subcutaneous deliver...Show More
Better Health for All
-20
Halozyme's ENHANZE® technology and distributed products have positively impacted over 600,000 patient lives across more than 100 global markets, with no evidence of negative health impacts.
1
Clinical data shows a 61% reduction in relapse risk for patients with Chronic Inflammatory Demyelinating Polyneuropathy and successful rapid delivery of high-volume biologics.
2
The company has achieved several years of exceptional safety outcomes with no government agency findings or corrective actions.
3
Halozyme provides transparency on research results and outcomes, enhances disclosures in SEC filings and on its website, and has robust adverse event reporting protocols.
4
The company made a $40 million upfront payment for a collaboration on HIV treatment and prevention.
5
Halozyme's employee base is 43.8% female and 30.5% non-white/Caucasian, with 35% female and 16.7% non-white/Caucasian in senior leadership as of December 2022.
6
The company offers various employee health benefits, including medical, dental, vision, and an Employee Assistance Program, and provides 16 hours of dedicated learning time annually per employee.
7
Preventative health measures include a wellness platform and virtual yoga classes.
8
Halozyme has robust data privacy and cybersecurity programs, using NIST and CIS frameworks, and its security controls were assessed above the industry average in 2022.
9
Mental health support includes access to multiple health plans and the launch of Modern Health in 2022.
10
The company supports STEM education programs for children.
11
Clinical trials adhere to ICH, GxP, Declaration of Helsinki, and PhRMA Code guidance, with a commitment to data transparency.
12
Fair Money & Economic Opportunity
0
No evidence available to assess Halozyme Therapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
20
In 2024, Halozyme's CEO to median employee pay ratio was 58:1.
1
The company reported a Total Recordable Incident Rate (TRIR) of 0.40 in 2024, with one OSHA recordable injury.
2
None of the company's employees are unionized.
3
The voluntary employee turnover rate was 9.6% in 2021, 18.3% in 2020, and 13.9% in 2022.
4
Employee engagement survey participation consistently achieved 92% or more, but the actual engagement score is not provided.
5
The company had no significant labor law infractions in the past two years.
Fair Trade & Ethical Sourcing
-60
Halozyme's key suppliers undergo biennial audits and reviews of their health, safety, and environmental programs.
1
The company expects all vendors and partners to affirm no use of child labor and has a Human Rights Statement, supporting the UN Universal Declaration of Human Rights, which it expects employees, contractors, suppliers, and business partners to abide by.
2
Halozyme also has an Anti-bribery policy and provides anti-corruption training to all employees.
3
However, there is no evidence provided regarding the percentage of supplier contracts that include enforceable ethical-sourcing clauses.
Honest & Fair Business
0
No evidence available to assess Halozyme Therapeutics, Inc. on Honest & Fair Business.
Kind to Animals
-20
Halozyme's core ENHANZE drug delivery technology utilizes rHuPH20, a recombinant human form of PH20, which replaces previously used animal-derived PH20 hyaluronidases (bovine and ovine).
1
This replacement is recommended by the World Health Organization.
2
However, the company conducts preclinical studies using animals, including minipigs, cynomolgus monkeys, CD-1 mice, and New Zealand White rabbits.
3
Halozyme states a commitment to the ethical use of animals in biomedical research and compliance with appropriate regulatory requirements, but its policy lacks specific measurable goals or consistent enforcement details beyond general adherence to regulations.
4
The company contracts with a nationally recognized CRO for these animal studies and has not disclosed the annual volume of animals used or transparent reduction goals.
5
Halozyme participates in industry forums but does not make commitments to collaborative initiatives for animal-free testing standards.
6
No War, No Weapons
0
No evidence available to assess Halozyme Therapeutics, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No specific, concrete data points were found in the provided articles to assess Halozyme Therapeutics, Inc. against the Planet-Friendly Business ethical value.
1
The single article provided indicated that no data could be extracted.
2
Respect for Cultures & Communities
0
No specific, concrete data points relevant to the 'Respect for Cultures & Communities' value or its associated KPIs were found in the provided articles. The articles either stated they were unavailable, were financial reports, or explicitly mentioned a lack of relevant information regarding community engagement, cultural impact, or related metrics.
Safe & Smart Tech
0
The company's privacy policy states that users have rights to access, delete, and request information, including data portability.
1
The policy also outlines data retention criteria for services, legal requirements, and contractual obligations.
2
Furthermore, the policy mentions compliance with US law and CCPA for California residents.
3
There are no documented incidents of unauthorized data use.
4
Zero Waste & Sustainable Products
0
No evidence available to assess Halozyme Therapeutics, Inc. on Zero Waste & Sustainable Products.